Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 11/20 | 0.48 |
| ▸ | TACR1 | P25103 | 6/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5156280 | 0.85 | REN (0.48) | RENTACR1MAPT | |
| SCHEMBL5161677 | 0.84 | TACR1 (0.70) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL4492783 | 0.83 | TACR1 (0.69) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL4492786 | 0.83 | TACR1 (0.69) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL4492777 | 0.83 | TACR1 (0.69) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5158455 | 0.78 | TACR1 (0.56) | TACR1SLC6A4TP53CYP1A2CYP3A4 | |
| SCHEMBL5158767 | 0.78 | SLC6A2 (0.46) | RENTACR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4496397 | 0.76 | TACR1 (0.55) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4496405 | 0.76 | TACR1 (0.55) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4496401 | 0.76 | TACR1 (0.55) | TACR1TP53CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | REN 610/4885TACR1 2/4885SLC6A2 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.